home / stock / pmvp / pmvp articles
PRINCETON, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discover...
PC14586 clinical program to be led by Deepika Jalota, Pharm.D. (Chief Development Officer) and Marc Fellous, M.D. (Senior Vice President, Head of...
Gainers Sigma Additive Solutions, Inc. (NASDAQ: SASI) shares jumped 196% to $7.34 after the company announced the signing of a definitive agreeme...
PRINCETON, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discove...
Gainers MicroAlgo Inc. (NASDAQ: MLGO) shares jumped 74% to $7.02 after it unveiled a knowledge-enhanced backtracking search algorithm to boost the...
Late-breaking poster presentation to highlight updated Phase 1 clinical data of PC14586, a first-in-class precision oncology investigational ther...
News, Short Squeeze, Breakout and More Instantly...
PMV Pharmaceuticals Inc. Company Name:
PMVP Stock Symbol:
NASDAQ Market:
2024-04-11 21:15:01 ET Jefferies analyst issues BUY recommendation for PMVP on April 11, 2024 07:46PM ET. PMVP was trading at $1.58 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy recommendations ...
2024-04-11 21:00:03 ET Kambiz Yazdi from Jefferies issued a price target of $5.00 for PMVP on 2024-04-11 19:46:00. The adjusted price target was set to $5.00. At the time of the announcement, PMVP was trading at $1.58. The overall price target consensus is at $31.33 with...
Rezatapopt is a first-in-class precision oncology investigational therapy for patients with advanced solid tumors with a TP53 Y220C mutation and KRAS wild-type (WT) First patient dosed in Phase 2 portion of the PYNNACLE trial which will assess rezatapopt as monotherapy in patients...